Develops biologically targeted boron neutron capture therapy (BNCT) for cancer treatment, combining boron-10 drugs with an in-hospital accelerator-based neutron delivery system called Alphabeam
Develops biologically targeted boron neutron capture therapy (BNCT) for cancer treatment, combining boron-10 drugs with an in-hospital accelerator-based neutron delivery system called Alphabeam. Its device and drugs are in development and are not yet available for sale or commercial use.